多梳蛋SUZ12预测吉西他滨治疗肝内胆管癌疗效和预后的研究

doi:10.11904/j.issn.1002-3070.2017.04.007

Abstract

Abstract: Objective This study explored the expression of polyclonal protein SUZ12 in patients with intrahepatic cholangiocarcinoma(ICC),and its role in predicting the survival and treatment of ICC patients.Methods The expression of SUZ12 and p16^INK4a was detected by immunohistochemical assay in 207 liver tissue samples including ICC patients,BilIN-1,-2,-3 and non-tumor-like cholangiocarcinoma.The expression of these proteins was assessed to be related to the pathological characteristics of the ICC patients receiving chemotherapy and the outcome of survival as well as the subsequent chemotherapy response.Results The expression level of SUZ12 was gradually increased from non-neoplastic bile duct tissue to BilIN-1,-2,-3 and ICC.The expression of p16^INK4a protein was expressed in non-neoplastic-like cholangiocarcinoma,but it decreased gradually in BilIN-1,-2,-3 and ICC tissues.SUZ12 expression was associated with undifferentiated ICC,lymph node metastasis and advanced cancer.Kaplan-Meier curve analysis showed that ICC patients with high expression of SUZ12 had a significant reduction in overall survival and disease-free survival in comparison with ICC patients with the low expression of SUZ12.SUZ12 expression was significantly associated with overall survival of patients receiving adjuvant gemcitabine-based chemotherapy(AGC).Conclusion SUZ12 expression is able to predict the overall survival and disease-free survival of ICC patients with adjuvant gemcitabine-based chemotherapy.

Key words: SUZ12, Intrahepatic cholangiocarcinoma, Gemcitabine, p16^INK4a

CLC Number:

R322.4

LIU Nan ,HAN Zhiyang ,LU Pengtian ,LI Danyang ,WANG Yingwei ,DONG Xianghui ,ZHU Hong. Expression of polycomb protein SUZ12 predicts poor prognosis and response of patients with intrahepatic cholangiocarcinoma to adjuvant gemcitabine-based chemotherapy[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 321-328.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2017.04.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2017/V31/I4/321

References

1 Okhotnikov OI,Yakovleva MV,Pakhomov VI.Percutaneous cholangiostomy for portal cholangiocarcinoma[J].Irurgiia(Mosk),2016,9:21-27.
2 Hamano G,Kubo S,Takemura S.Comparison of clinicopathological characteristics between patients with occupational and non-occupational intrahepatic cholangiocarcinoma[J].J Hepatobiliary Pancreat Sci,2016,23(7):389-396.
3 Vijgen S,Terris B,Rubbia-Brandt L.Pathology of intrahepatic cholangiocarcinoma[J].Hepatobiliary Surg Nutr,2016,6(1):22-34.
4 Hirano S,Kondo S,Tanaka E,et al.Outcome of surgical treatment of hilar cholangiocarcinoma:a special reference to postoperative morbidity and mortality[J].J Surg Case Rep,2010,17(4):455-462.
5 Murakami Y,Uemura K,Sudo T,et al.Prognostic factors after surgical resection for intrahepatic,hilar,and distal cholangiocarcinoma[J].Ann Surg Oncol,2011,18(3):651-658.
6 Wang X,Goodrich KJ,Gooding AR.Targeting of polycomb repressive complex 2 to RNA by short repeats of consecutive guanines[J].Mol Cell,2017,65(6):1056-1067.
7 Toyokawa G,Takada K,Okamoto T.Elevated metabolic activity on ¹⁸F-FDG PET/CT is associated with the expression of EZH2 in non-small cell lung cancer[J].Anticancer Res,2017,37(3):1393-1401.
8 Eleutério J Jr,Lima TS,Cunha MD,et al.Immunohistochemical expression of the tumor suppressor protein p16^INK4a in cervical adenocarcinoma[J].Rev Bras Ginecol Obstet,2017,39(1):21-25.
9 Taniai M,Higuchi H,Burgart LJ,et al.p16^INK4a promoter mutations are frequent in primary sclerosing cholangitis(PSC)and PSC-associated cholangiocarcinoma[J].Gastroenterology,2002,123(4):1090-1098.
10 Kirmizis A,Bartley SM,Farnham PJ.Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy[J].Mol Cancer Ther,2003,2(1):113-121.
11 Cui Y,Chen J,He Z,et al.SUZ12 depletion suppresses the proliferation of gastric cancer cells[J].Cell Physiol Biochem,2013,31(6):778-784.
12 Pasini D,Bracken AP,Jensen MR,et al.Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity[J].EMBO J,2004,23(20):4061-4071.
13 Ishikawa A,Sasaki M,Sato Y,et al.Frequent p16ink4a inactivation is an early and frequent event of intraductal papillary neoplasm of the liver arising in hepatolithiasis[J].Hum Pathol,2004,35(12):1505-1514.

[1]	SUN Yipeng, NI Zhenhua, WU Yingying, CHEN Qingge, BI Junjie, LIN Yuhua, WANG Xiongbiao. Overexpression of CLPTM1L inhibits the sensitivity of 95-D lung cancer cells to gemcitabine [J]. Journal of Practical Oncology, 2019, 33(6): 486-490.
[2]	ZHAO Lifeng,CHENG Weihua,LEI Da,YANG Yanwei,WANG Gang. The relationship between DKK1 protein expression and lymph node invasion,and prognosis in patients with intrahepatic cholangiocarcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 228-233.
[3]	WU Yiqi, LUI Ying, ZHAO Li, JIN Xiaoming. Detection of hepatitis B virus protein and gene in intrahepatic and extrahepatic cholangiocarcinoma tissue [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 7-12.
[4]	LU Ying,HUANG Haixin,LI Guisheng. GEMOX regimen in treatment of relapsed or refractory non-Hodgkin′s lymphoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(6): 547-550.
[5]	ZHANG Minghui, ZHANG Qingyuan, ZHAO Shu, WANG Xiaochuan, MA Wenjie, XU Shanqi, SUN Yan. Clinical observation of GP and NP regimen in patients with advanced breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(3): 247-251.
[6]	LI Jing, ZHANG Hua. Clinical research of combined gemcitabine with Xiaoaiping injection on advanced non-small cell lung cancer:lower toxicity and higher efficacy [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 307-310.
[7]	WANG Genhe, FANG Ping, WU Yiqing, WANG Yuanfei. Treatment of advanced non-small-cell lung cancer with gemcitabine plus cisplatin in the elderly patients compared with in the younger [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 325-327.
[8]	ZOU Lijuan, XU Xiaoying, WANG Ruoyu, SHAO Shujuan. Experimental study on the injury of rat spinal cord made by gemcitabine and cisplatin combined chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(2): 139-141.

Expression of polycomb protein SUZ12 predicts poor prognosis and response of patients with intrahepatic cholangiocarcinoma to adjuvant gemcitabine-based chemotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments